TheraGenetics, a London biotechnology company developing personalized-medicine diagnostics, raised $6 million (£3 million) in a first funding round. The company is working on a diagnostic test designed to predict which patients are most likely to respond to antipsychotic drugs, including those for schizophrenia.
Swarraton Partners led the round, joined by Tudor Capital, IP Venture Fund, and IP Group. TheraGenetics was spun out of the King’s College Institute of Psychiatry.
1 Comment »
